Association of the manganese superoxide dismutase gene Ala-9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 4, 2010, Pages 692-696

  Liu, Hong ^a,b   Wang, Cui ^c   Chen, Pin Hong ^d   Zhang, Ben Shu ^a   Zheng, You Lan ^c   Zhang, Chong Xi ^e   Meng, Hua Qing ^d   Wang, Yu ^a   Chen, Da Chun ^f   Xiu, Mei Hong ^f   Kosten, Thomas R ^g   Zhang, Xiang Yang ^f,g  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b CHANGZHI MEDICAL COLLEGE   (China)

^c JILIN AGRICULTURAL UNIVERSITY   (China)

^d CHONGQING MEDICAL UNIVERSITY   (China)

^e SHANDONG UNIVERSITY   (China)

^f BEIJING HUILONGGUAN HOSPITAL   (China)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Association; Manganese superoxide dismutase; Polymorphism; Schizophrenia; Tardive dyskinesia

Indexed keywords

ALANINE; ATYPICAL ANTIPSYCHOTIC AGENT; MANGANESE SUPEROXIDE DISMUTASE; NEUROLEPTIC AGENT; VALINE;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; PHENOTYPE; POSITIVE AND NEGATIVE SYNDROME SCALE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA;

ADULT; AGED; ALLELES; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DYSKINESIA, DRUG-INDUCED; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SUPEROXIDE DISMUTASE;

EID: 77952671414     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.03.026     Document Type: Article

References (35)

1. Akyol O., Yanik M., Elyas H., Namli M., Canatan H., Akin H., et al. Association between Ala-9Val polymorphism of Mn-SOD gene and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:123-131.
2. Bakker P.R., van Harten P.N., van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a metaanalysis of pharmacogenetic interactions. Mol Psychiatry 2008, 13:544-556.
3. Basile V.S., Masellis M., Potkin S.G., Kennedy J.L. Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 2002, 11:2517-2530.
4. Buckman T.D., Kling A., Sutphin M.S., Steinberg A., Eiduson S. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables. Psychiatry Res 1990, 31:1-14.
5. Caligiuri M.P., Lacro J.P., Rockwell E., McAdams L.A., Jeste D.V. Incidence and risk factors for severe tardive dyskinesia in older patients. Br J Psychiatry 1997, 171:148-153.
6. Cubells J.F., Kobayashi K., Nagatsu T., Kidd K.K., Kidd J.R., Calafell F., et al. Population genetics of a functional variant of the dopamine beta-hydroxylase gene (DBH). Am J Med Genet 1997, 74:374-379.
7. Hiroi S., Harada H., Nishi H., Satoh M., Nagai R., Kimura A. Polymorphisms in the SOD2 and HLA-DRB1 genes are associated with nonfamilial idiopathic dilated cardiomyopathy in Japanese. Biochem Biophys Res Commun 1999, 261:332-339.
8. Hitzeroth A., Niehaus D.J., Koen L., Botes W.C., Deleuze J.F., Warnich L. Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:664-672.
9. Hori H., Ohmori O., Shinkai T., Kojima H., Okano C., Suzuki T., et al. Manganese superoxide dismutase gene polymorphism and schizophrenia: Relation to tardive dyskinesia. Neuropsychopharmacology 2000, 23:170-177.
10. Kang S.G., Choi J.E., An H., Park Y.M., Lee H.J., Han C., et al. Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(8):1844-1847.
11. Lindholm E., Ekholm B., Shaw S., Jalonen P., Johansson G., Pettersson U., et al. A schizophrenia-susceptibility locus at 6q25, in one of the world's largest reported pedigrees. Am J Hum Genet 2001, 69:96-105.
12. Lohr J.B., Kuczenski R., Bracha H.S., Moir M., Jeste D.V. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 1990, 28:535-539.
13. Lohr J.B. Oxygen radicals and neuropsychiatric illness. Some speculations. Arch Gen Psychiatry 1991, 48:1097-1106.
14. Lohr J.B., Browning J.A. Free radical involvement in neuropsychiatric illnesses. Psychopharmacol Bull 1995, 31:159-165.
15. Lohr J.B., Kuczenski R., Niculescu A.B. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003, 17:47-62.
16. Mahadik S.P., Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 1996, 19:1-17.
17. McCreadie R.G., Thara R., Kamath S., Padmavathy R., Latha S., Mathrubootham N., et al. Abnormal movements in never-medicated Indian patients with schizophrenia. Br J Psychiatry 1996, 168:221-226.
18. Müller D.J., Schulze T.G., Knapp M., Held T., Krauss H., Weber T., et al. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand 2001, 104:375-379.
19. Müller D.J., Shinkai T., De Luca V., Kennedy J.L. Clinical implications of pharmacogenomics for tardive dyskinesia. Pharmacogenomics J 2004, 4(2):77-87.
20. Pae C.U., Kim T.S., Patkar A.A., Kim J.J., Lee C.U., Lee S.J., et al. Manganese superoxide dismutase (MnSOD: Ala-9Val) gene polymorphism may not be associated with schizophrenia and tardive dyskinesia. Psychiatry Res 2007, 153:77-81.
21. Pae C.U. Additive effect between quinine oxidoreductase gene (NQO1: Pro187Ser) and manganese superoxide dismutase gene (MnSOD: Ala-9Val) polymorphisms on tardive dyskinesia in patients with schizophrenia. Psychiatry Res 2008, 161:336-338.
22. Reddy R.D., Yao J.K. Free radical pathology in schizophrenia: a review. Prostaglandins Leukot Essent Fat Acids 1996, 55:33-43.
23. Robinson B.H. The role of manganese superoxide dismutase in health and disease. J Inherit Metab Dis 1998, 21:598-603.
24. Schooler N.R., Kane J.M. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982, 39:486-487.
25. Shimoda-Matsubayashi S., Matsumine H., Kobayashi T., Nakagawara-Hattori Y., Shimizu Y., Mizuno Y. Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. Biochem Biophys Res Comm 1996, 226:561-565.
26. Shimoda-Matsubayashi S., Hattori T., Matsumine H., Shinohara A., Yoritaka A., Mori H., et al. MnSOD activity and protein in a patient with chromosome 6-linked autosomal recessive parkinsonismin comparisonwith Parkinson's disease and control. Neurology 1997, 49:1257-1262.
27. Tsai G., Goff D.C., Chang R.W., Flood J., Baer L., Coyle J.T. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 1998, 155:1207-1213.
28. van Os J., Fahy T., Jones P., Harvey I., Toone B., Murray R. Tardive dyskinesia: who is at risk?. Acta Psychiatr Scand 1997, 96:206-216.
29. van Os J., Walsh E., van Horn E., Tattan T., Bale R., Thompson S.G. Changes in negative symptoms and the risk of tardive dyskinesia: a longitudinal study. UK700 Group. Acta Psychiatr Scand 2000, 101:300-306.
30. Yamada K., Kanba S., Anamizu S., Ohnishi K., Ashikari I., Yagi G., et al. Low superoxide dismutase activity in schizophrenic patients with tardive dyskinesia. Psychol Med 1997, 27:1223-1225.
31. Yao J.K., Reddy R.D., van Kammen D.P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001, 15:287-310.
32. Zai C.C., Tiwari A.K., Basile V., de Luca V., Müller D.J., Voineskos A.N., et al. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:50-56.
33. Zhang X.Y., Zhou D.F., Cao L.Y., Chen D.C., Zhu F.Y., Wu G.Y. Blood superoxide dismutase level in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr Res 2003, 62:245-250.
34. Zhang X.Y., Tan Y.L., Zhou D.F., Cao L.Y., Wu G.Y., Haile C.N., et al. Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. J Clin Psychiatry 2007, 68:754-760.
35. Zhang Z.J., Zhang X.B., Hou G., Sha W.W., Reynolds G.P. The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia in untreated to the Ala-9Val polymorphism. J Psychiatry Res 2002, 36:317-324.